Abstract
Euglobal-IIIa (1), a novel acylphloroglucinol-sesquiterpene derivative, and a known analogue, have been isolated from leaves of Eucalyptus robusta. The structures was elucidated by extensive spectroscopic data and by comparison with data reported in literature, while the absolute configuration of 1 was determined by the X-ray diffraction analysis. Compound 1 exhibited comparable cytotoxicity with that of cisplatin against five human cancer cell lines HL-60, SMMC-7721, A-549, MCF-7, and SW480 with IC50 values of 15.7, 15.5, 17.6, 14.3, and 21.8 µM, respectively. Electronic Supplementary MaterialSupplementary material is available for this article at 10.1007/s13659-011-0021-9 and is accessible for authorized users.
Highlights
Euglobals are a group of caryophyllene-based monoterpenoid derivatives which have been found to be abundant in the genus Eucalyptus.[1]
As part of our efforts to search for significant antitumor agents, a novel acylphloroglucinol-sesquiterpene derivative, named euglobal-IIIa (1), and a known analogure, were isolated from leaves of E. robusta Smith, a tree up to 20 meters distributed in Yunnan and Sichuan province, China
The structure of 1 was established on the basis of extensive spectroscopic methods and the absolute configuration was determined by the single crystal X-ray diffraction analysis, while the known compound was identified as sideroxylonal B (2) by comparison with data reported in literature.[3]
Summary
Euglobals are a group of caryophyllene-based monoterpenoid (or sesquiterpenoid) derivatives which have been found to be abundant in the genus Eucalyptus.[1]. The structure of 1 was established on the basis of extensive spectroscopic methods and the absolute configuration was determined by the single crystal X-ray diffraction analysis, while the known compound was identified as sideroxylonal B (2) by comparison with data reported in literature.[3] The cytotoxicity of two compounds against five human cancer cell lines was evaluated.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
